TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01418820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum stimulation
Description: 10 days (2x 5 working days), daily transorbital alternating current stimulation (rtACS) is applied with a device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 µA. Current intensity is individually adjusted according to how well patients perceived phosphenes, e.g. any sensation of flickering light in response to the rtACS stimulation. Stimulation frequencies were between the individual alpha frequency peak and below flicker fusion.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo stimulation
Description: 10 days (2x 5 working days), daily sham-stimulation with the same electrode montage set-up that is used for verum transorbital alternating current stimulation (rtACS). Minimal sham-stimulation was performed with single bursts (approx. one per min) of electrical currents at a given frequency of 5Hz and individually adjusted current amplitude.
Study: NCT06402981

Intervention type: OTHER
Intervention: High risk prediction model for liver injury
Description: Risk Prediction Model for Liver Injury After Use of PD-1/PD-L1 Inhibitors

Intervention type: OTHER
Intervention: High risk prediction model for liver injury
Description: Risk Prediction Model for Liver Injury After Use of PD-1/PD-L1 Inhibitors
Study: NCT02183532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS
Description: multiple doses
Study: NCT01238367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Subjects will receive recombinant factor VIII (N8) at a dose of 50 +/- 5 IU/kg body weight. Intravenous administration as a single bolus injection.
Study: NCT03307499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeoPatch
Description: NeoPatch as an adjunct to foot and ankle tendon revision/repair surgery
Study: NCT03529695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard HVP Curriculum
Description: Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on strengthening children's cognitive skills, early literacy skills, social/emotional and physical development.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard HVP Curriculum
Description: Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on strengthening children's cognitive skills, early literacy skills, social/emotional and physical development.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Obesity Prevention
Description: Obesity prevention curriculum program targets 4 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, and decreasing fried foods) aimed at reducing obesity risk in mothers and children. The module will also include weekly activity opportunities to develop social networks that foster healthy eating and physical activity.
Study: NCT04322890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib 80mg, po, qd;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib 150 MG
Description: Alectinib 600mg, po, qd; Lorlatinib, 100mg, po, qd;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 MG
Description: Crizotinib 250 MG po bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib, Crizotinib.
Description: Savolitinib, 300mg po qd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: 500mg, ivgtt, every 21day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: 500mg, ivgtt, every 21day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: 500mg, ivgtt, every 21day.
Study: NCT03236246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRX-0502
Description: Oral ferric citrate with meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRX-0502
Description: Oral ferric citrate with meals
Study: NCT05817760

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Z-scrotoplasty
Description: Z shape incision of the penoscrotal web and closure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heineke-Mikulicz scrotoplasty
Description: Transverse incision of the penoscrotal web with vertical closure
Study: NCT03249077

Intervention type: BEHAVIORAL
Intervention: Digital DPP
Description: The online DPP program is 12 months in duration with 16 core sessions delivered over 16-26 weeks and 6 maintenance sessions delivered over 6 months.

Intervention type: BEHAVIORAL
Intervention: In-person DPP
Description: The in-person DPP program is 12 months and consists of weekly sessions for the first 6 months and monthly sessions for the remaining 6 months.

Intervention type: OTHER
Intervention: DPP not enrolled
Description: Access to usual care services without restrictions.
Study: NCT00462865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Capecitabine and Avastin
Description: avastin administered concurrently with chemotherapy (gemcitabine + capecitabine) for six cycles followed by single agent avastin to complete one year of treatment. Radiation therapy (if planned) will take place after adjuvant chemotherapy completes.
Study: NCT02410941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical decision support
Description: Establish evidence-based standardized clinical pathways implemented by local communities of practice focused on imaging utilization in ED settings as models of participatory research and integrated knowledge translation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical decision support
Description: Establish evidence-based standardized clinical pathways implemented by local communities of practice focused on imaging utilization in ED settings as models of participatory research and integrated knowledge translation.
Study: NCT01398293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 100 mg single dose orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 400 mg single dose orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danoprevir placebo
Description: single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: danoprevir placebo
Description: single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: 400 mg single dose orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin placebo
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin placebo
Description: single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: moxifloxacin placebo
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg single dose orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg single dose orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir placebo
Description: single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ritonavir placebo
Description: single oral dose
Study: NCT02328287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLOB®
Description: Each patient will undergo a single administration of ALLOB® into the failed fusion lumbar level under anesthesia.
Study: NCT05629650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi for memory
Description: The adapted form of TCM will be provided at 60 minutes per session, twice a week for 12 weeks by a certified Tai Chi instructor who had experience in teaching older adults with cognitive impairments.
Study: NCT02153372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMC2012
Study: NCT02864381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: 800 mg administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg administered via IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: 3 mg/kg administered via IV infusion
Study: NCT01903018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P276-00

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT02120625

Intervention type: DEVICE
Intervention: Lumbar MB RFN
Description: Patients will be placed in a prone position and prepped. The C-arm will be adjusted to establish a true anteroposterior image of the target vertebra. The C-arm will then be rotated until the target point at the base of the SAP is clearly visualized. The Nimbus probe, with the tines (filaments) in the retracted position, will be inserted and advanced to the bony target site using a down the beam approach. The probe hub will be rotated to accomplish a full deployment of the tines with a medial or lateral angular bias, as dictated by the SAP anatomy and angle of entry of the NMEE probe. Motor stimulation at 2 Hz up to 2 volts will be administered (safety check). The lesion site will be anesthetized before the radiofrequency (RF) generator is set to achieve a temperature of 80°C for 80 seconds, following 30 second temperature ramp up. Impedance and power will be recorded.
Study: NCT04544345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: His bundle pacing, AV optimized
Description: A Select Secure 3830 (Medtronic, MN, USA) pacing lead will be placed on the bundle of His. In case of unsuccessful His capture, left bundle branch area pacing is going to be targeted. Pacemaker will be programmed to a low base rate and a high tracking rate to allow for intrinsic sinus rhythm. AV delay will be optimized with echocardiography to the shortest AV delay without truncation of the A wave on transmitral pulse wave doppler.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Backup VVI pacing
Description: Pacemaker will be programmed to VVI (ventricular only) mode with low base rate as to allow for intrinsic sinus rhythm without AV optimization.
Study: NCT04010513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Women in the hypnosis group will undergo treatment with three in-person hypnosis sessions and will be given access to hypnosis web-app for at home practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Women in the usual care group will continue their usual care for BPS/IC as dictated by their physicians.
Study: NCT00234494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 70 mg/m2, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1250 mg/m2, day 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15mg/kg, day 1
Study: NCT03205215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: 100% oxygen delivered by hood at 2 ATA for 90 minutes with 5 minute air breaks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waitlist Hyperbaric Oxygen Therapy
Description: 100% oxygen delivered by hood at 2 ATA for 90 minutes with 5 minute air breaks
Study: NCT01409863

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: laser and standard diamond fraise dermabrasion
Description: standard dermabrasion, CO2 laser resurfacing
Study: NCT00667355

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40 mg or 80 mg every other week, subcutaneous
Study: NCT00616434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG9418 (Interferon beta-1a)
Description: Avonex IM injection, self-administered per protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IM injection, self-administered per protocol.
Study: NCT02212873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyBFF@school program
Description: Students will be required to participate in all 3 components of MyBFF@school (SSG, nutrition and psychology sessions) for 16 weeks under the supervision of trained researchers, then for another 16 weeks supervised by their respective teachers-in-charge of physical education and/or co-curriculum activity. Each SSG session will be for an hour, thrice weekly while the nutrition or psychology session will be for 30-45 minutes once a week.
Study: NCT04471948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional picosecond 1064 nm laser
Description: The parameter of laser was 8 mm spot size, 0.8 mJ/CM2, 750 ps, 5 Hz, 2 passes The treatment was done in every 4 weeks for 3 sessions.
Study: NCT04279262

Intervention type: OTHER
Intervention: attendance by community first responders for medical emergencies
Description: The investigators will purposively sample patients, relatives, and ambulance staff identified from records of patients who have been attended by a CFR in a rural location in the previous six months. Where possible the investigators will interview patients, relatives, CFRs and ambulance staff attending the same event. GPs will be purposively sampled from rural areas of the ambulance services involved. Investigators will recruit a maximum variation sample of patients (according to age, sex, condition, and ethnicity), ambulance staff (sex, experience, ethnicity and role), CFR (sex, ethnicity, length of experience, skill level) and CFR scheme leads (independent charity and ambulance trust overseen schemes).

Intervention type: OTHER
Intervention: attendance by community first responders for medical emergencies
Description: The investigators will purposively sample patients, relatives, and ambulance staff identified from records of patients who have been attended by a CFR in a rural location in the previous six months. Where possible the investigators will interview patients, relatives, CFRs and ambulance staff attending the same event. GPs will be purposively sampled from rural areas of the ambulance services involved. Investigators will recruit a maximum variation sample of patients (according to age, sex, condition, and ethnicity), ambulance staff (sex, experience, ethnicity and role), CFR (sex, ethnicity, length of experience, skill level) and CFR scheme leads (independent charity and ambulance trust overseen schemes).
Study: NCT00347672

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)
Description: Live, attenuated recombinant H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca) vaccine (one of three doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)
Description: Live, attenuated recombinant H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca) vaccine (one of three doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)
Description: Live, attenuated recombinant H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca) vaccine (one of three doses)
Study: NCT04012437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sphincter Control Training (SCT)
Description: The SCT + device consists of 8 different exercises and an educational session into a app using a masturbation electronic aid device

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sphincter Control Training (SCT)
Description: The SCT consists of 4 different exercises and an educational session into a app using a masturbation electronic aid device
Study: NCT01753154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solution B (balance PD solution)
Description: balance 1.5% glucose, solution for peritoneal dialysis; balance 2.3% glucose, solution for peritoneal dialysis; balance 4.25% glucose, solution for peritoneal dialysis, each with 1.25 mmol/l or 1.75 mmol/l calcium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solution A (conventional PD solution)
Description: Solutions for peritoneal dialysis: CAPD 2 (1.5% glucose, 1.75mmmol/l calcium), CAPD 3 (4.25 % glucose, 1.75mmmol/l calcium), CAPD 4 (2.3% glucose, 1.75mmmol/l calcium), CAPD 17 (1.5% glucose, 1.25mmmol/l calcium), CAPD 18 (4.25% glucose, 1.25mmmol/l calcium) and CAPD 19 (2.3% glucose, 1.25mmmol/l calcium)
Study: NCT01612741

Intervention type: DRUG
Intervention: Acarbose (Precose/Glucobay, BAYG5421)
Description: Oral Glucobay 25 titrated to Glucobay 50 three times a day with meals or as per investigators descretion.
Study: NCT00556153

Intervention type: DRUG
Intervention: [F-18]Fluoro-DOPA PET, a diagnostic radiopharmaceutical
Description: A single dosage of the diagnostic drug will be administered to individuals who meet inclusion criteria after informed consent.
Study: NCT01681134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf®
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf®
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf®
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf®
Description: oral
Study: NCT04356248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance Training
Description: Treatment in both arms consists of specific endurance exercise modalities (HIIT or ST). Treatments differ in the applied training intensities. Participants in both arms will exercise 3 times per week over a period of 3 weeks on a bicycle ergometer. Exercise sessions will be supervised by a trained physical therapist. Exercise intensity will be heart rate monitored based on the maximum heart rate (HRmax) assessed during the initial cardiopulmonary exercise test. Exercise sessions in both arms will include a warm-up and a cool-down period at low intensity (50% HRmax) for 3 min each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Endurance Training
Description: Treatment in both arms consists of specific endurance exercise modalities (HIIT or ST). Treatments differ in the applied training intensities. Participants in both arms will exercise 3 times per week over a period of 3 weeks on a bicycle ergometer. Exercise sessions will be supervised by a trained physical therapist. Exercise intensity will be heart rate monitored based on the maximum heart rate (HRmax) assessed during the initial cardiopulmonary exercise test. Exercise sessions in both arms will include a warm-up and a cool-down period at low intensity (50% HRmax) for 3 min each.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Treatment in both arms consists of specific energy management education interventions (IEME or PMR). Treatments differ in the applied education approaches. Participants in both arms will exercise 2 times per week over a period of 3 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Treatment in both arms consists of specific energy management education interventions (IEME or PMR). Treatments differ in the applied education approaches. Participants in both arms will exercise 2 times per week over a period of 3 weeks.
Study: NCT01679366

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet 2 times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: 1 tablet twice daily
Study: NCT05104008

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lateral wedge insoles with home exercises group(Group 1)
Description: In this group, participants were advised to use lateral wedge insole during walking and long-standing. Non customized full-length lateral wedge insoles of 7mm made of silicon material with 5 degrees angulation (because greater wedging is associated with foot discomfort) was used. Full-length wedge extends under the lesser metatarsal heads which increases the lever arm for rearfoot eversion and thus can prevent subtalar joint rotation. The evaluations were performed every week till fourth week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physiotherapy with home exercises group (Group 2)
Description: Each participant received 40-45 minutes long session, started in lying position. The therapeutic low-intensity pulsed ultrasound (US) was used for 7 minutes with the frequency of 1 MHz, Spatial Average Intensity was 0.2 W /cm2, pulsed duty cycle 20%, therapeutic dose was 112.5 J/cm2 with fixed application on the medial side of the knee joint. The model of US was Unit Intelect Mobile, (Chattanooga Inc). After US therapy passive stretching of calf, hamstring, quadriceps, hip flexors, adductors \& abductor s was done, which was followed by the manual strengthening exercises and strengthening with quadriceps bench. The session was repeated thrice a week and 12 sessions per month. The home program was guided in both groups including avoiding low sitting, cross leg sitting along with Isometrics of quadriceps atleast 3 times a day, with 5-10 seconds hold of each contraction.
Study: NCT01777087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gauze soaked with capsaicin
Description: This is a basic science study determining the brain activation that results from painful stimulation. All subjects will have the same painful stimulations and brain images collected.